올리고뉴클레오티드 합성 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Oligonucleotide Synthesis Market was valued at USD 2.8 billion in 2025 and is estimated to grow at a CAGR of 12.5% to reach USD 8.6 billion by 2035.

Market expansion is driven by the growing pipeline of oligonucleotide therapeutics, the rising adoption of synthetic oligonucleotides across research and clinical settings, and the increasing commercialization of precision medicine and gene-editing technologies. Oligonucleotide synthesis continues to be a critical enabling technology across the life sciences sector, supplying essential nucleic acid components for therapeutic development, molecular research, and synthetic biology initiatives. Ongoing investments in manufacturing capabilities by leading commercial synthesis providers, together with sustained demand from multiple end-use industries, are expected to reinforce long-term market growth. Furthermore, the expanding implementation of molecular diagnostic solutions and precision medicine approaches continues to strengthen demand for synthetic oligonucleotides, which remain indispensable components in a wide range of genomic and molecular analysis applications across healthcare and research settings.

The products and services segment accounts for 53% share and is forecast to grow at a CAGR of 12.05% between 2026 and 2035. This segment includes commercial synthesis solutions that deliver research-grade, analytical-grade, and GMP-grade oligonucleotides designed to meet customer-specific sequence lengths, purity specifications, and chemical modification requirements. Its leading market position reflects the indispensable role of synthesis services as the foundation for virtually every downstream application, supporting activities ranging from scientific research to advanced pharmaceutical development and commercial manufacturing.

The pharmaceutical and biotechnology companies segment held 55% share and is projected to register a CAGR of 12.65% throughout 2035. Their market leadership is supported by the increasing reliance on synthetic oligonucleotides across multiple stages of drug development, including target discovery, lead optimization, preclinical evaluation, clinical manufacturing, and commercial production. To strengthen supply reliability and ensure uninterrupted manufacturing capacity, many organizations are entering long-term partnerships with GMP-certified synthesis providers, highlighting the strategic importance of dependable production capabilities for advancing oligonucleotide-based drug development programs and maintaining regulatory and operational continuity.

North America Oligonucleotide Synthesis Market captured USD 955.9 million in 2025, supported by its well-established pharmaceutical and biotechnology ecosystem and extensive research infrastructure. The United States generates most of the regional revenue, benefiting from consistent federal research funding, a strong concentration of clinical-stage biotechnology companies, and the presence of several leading providers specializing in oligonucleotide synthesis technologies and manufacturing services.

Key companies operating in the global oligonucleotide synthesis market include Thermo Fisher Scientific, Integrated DNA Technologies, LGC Biosearch Technologies, Bioneer, Eurogentec, Azenta Life Sciences, Eurofins, Maravai LifeSciences, GenScript, Twist Bioscience, Merck, and Agilent. Companies operating in the oligonucleotide synthesis market are strengthening their market position by expanding manufacturing capacity, enhancing GMP-compliant production capabilities, and investing in advanced synthesis technologies that improve scalability, quality, and turnaround times. Many participants are broadening their product portfolios through the introduction of customized oligonucleotide solutions with diverse purity levels and chemical modifications to address evolving customer requirements. Strategic collaborations with pharmaceutical companies, biotechnology firms, and research organizations remain a key approach for securing long-term business opportunities and supporting drug development pipelines. Organizations are also focusing on geographic expansion by establishing new production facilities and strengthening regional distribution networks.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy & data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail & confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Base year calculation for any one approach
• 1.8 Forecast model
  • 1.8.1 Quantified market impact analysis
    • 1.8.1.1 Mathematical impact of growth parameters on forecast
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product type trends
  • 2.2.3 Application trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Expanding Applications in Molecular Diagnostics and Precision Medicine.
    • 3.2.1.2 Growing Prevalence of Diseases Globally.
    • 3.2.1.3 Rapid Technology Advancements in Synthetic Biology.
    • 3.2.1.4 Rising Investments Towards Research and Development Activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent Government Regulations and Guidelines.
    • 3.2.2.2 High Cost, Biosafety, Biosecurity, and Ethical Issues.
  • 3.2.3 Market opportunities
    • 3.2.3.1 Untapped Potential in Emerging Markets for Research-Grade Oligo Demand
    • 3.2.3.2 Emergence of High-Complexity Oligo Pools for Synthetic Biology & CRISPR Screening
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing trend analysis (Driven by Primary Research)
• 3.7 Future market trends
• 3.8 Impact of AI & Generative AI on the market (Driven by Primary Research)
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Oligonucleotide Synthesis
  • 5.2.1 Standard oligonucleotide synthesis
  • 5.2.2 Custom oligonucleotide synthesis
• 5.3 Reagents and Consumables
• 5.4 Equipments

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Research
  • 6.2.1 Synthetic biology
  • 6.2.2 Drug discovery
  • 6.2.3 Other research applications
• 6.3 Therapeutics
  • 6.3.1 Neurology
  • 6.3.2 Rare diseases
  • 6.3.3 Cardiovascular disease
  • 6.3.4 Infectious diseases
  • 6.3.5 Other therapeutic areas
• 6.4 Diagnostics

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Pharmaceutical and biotechnology companies
• 7.3 Academic and research institutes
• 7.4 Contract research organization
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Agilent Technologies
• 9.2 Azenta Life Sciences
• 9.3 Bioneer
• 9.4 Eurofins
• 9.5 Eurogentec
• 9.6 GenScript
• 9.7 Integrated DNA Technologies
• 9.8 LGC Biosearch Technologies
• 9.9 Maravai LifeSciences
• 9.10 Merck
• 9.11 Thermo Fisher Scientific
• 9.12 Twist Bioscience